+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Allergic Rhinitis - Pipeline Review, H1 2020

  • ID: 5024709
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 164 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Advagene Biopharma Co Ltd
  • ASIT Biotech SA
  • HAL Allergy BV
  • Link Health Group
  • Oneness Biotech Co Ltd
  • Shouyao Holding Co Ltd
  • MORE
Allergic Rhinitis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H1 2020, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 5, 12, 9, 2, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 5 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Advagene Biopharma Co Ltd
  • ASIT Biotech SA
  • HAL Allergy BV
  • Link Health Group
  • Oneness Biotech Co Ltd
  • Shouyao Holding Co Ltd
  • MORE
  • Introduction
  • Allergic Rhinitis - Overview
  • Allergic Rhinitis - Therapeutics Development
  • Allergic Rhinitis - Therapeutics Assessment
  • Allergic Rhinitis - Companies Involved in Therapeutics Development
  • Allergic Rhinitis - Drug Profiles
  • Allergic Rhinitis - Dormant Projects
  • Allergic Rhinitis - Discontinued Products
  • Allergic Rhinitis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Allergic Rhinitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by ALK-Abello AS, H1 2020
  • Allergic Rhinitis - Pipeline by Allovate LLC, H1 2020
  • Allergic Rhinitis - Pipeline by AOBiome LLC, H1 2020
  • Allergic Rhinitis - Pipeline by ASIT Biotech SA, H1 2020
  • Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
  • Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Dobecure SL, H1 2020
  • Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, H1 2020
  • Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2020
  • Allergic Rhinitis - Pipeline by Inimmune Corp, H1 2020
  • Allergic Rhinitis - Pipeline by Inmunotek SL, H1 2020
  • Allergic Rhinitis - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H1 2020
  • Allergic Rhinitis - Pipeline by Link Health Group, H1 2020
  • Allergic Rhinitis - Pipeline by Marinomed Biotech AG, H1 2020
  • Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
  • Allergic Rhinitis - Pipeline by Navipharm Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Novartis AG, H1 2020
  • Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H1 2020
  • Allergic Rhinitis - Pipeline by Sam-A Pharm Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, H1 2020
  • Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, H1 2020
  • Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, H1 2020
  • Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H1 2020
  • Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, H1 2020
  • Allergic Rhinitis - Pipeline by United Biomedical Inc, H1 2020
  • Allergic Rhinitis - Pipeline by Vactech Oy, H1 2020
  • Allergic Rhinitis - Pipeline by Wolwo Pharma, H1 2020
  • Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Allergic Rhinitis - Discontinued Products, H1 2020
  • Allergic Rhinitis - Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
  • Number of Products under Development for Allergic Rhinitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • Advagene Biopharma Co Ltd
  • ALK-Abello AS
  • Allovate LLC
  • AOBiome LLC
  • ASIT Biotech SA
  • Chrysalis BioTherapeutics Inc
  • CSPC Pharmaceutical Group Ltd
  • Dobecure SL
  • Emergo Therapeutics Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • HAL Allergy BV
  • Inimmune Corp
  • Inmunotek SL
  • JiangSu Qyuns Therapeutics Co Ltd
  • Kolmar Korea Holdings Co Ltd
  • Laboratorios LETI SL
  • Link Health Group
  • Marinomed Biotech AG
  • Mitsubishi Tanabe Pharma Corp
  • Navipharm Co Ltd
  • Novartis AG
  • Oneness Biotech Co Ltd
  • Paradigm Biopharmaceuticals Ltd
  • Regeneron Pharmaceuticals Inc
  • Roxall Medizin GmbH
  • Sam-A Pharm Co Ltd
  • Sedor Pharmaceuticals LLC
  • Shouyao Holding Co Ltd
  • Siolta Therapeutics Inc
  • Stallergenes Greer plc
  • The Geneva Biotech Center SA
  • United Biomedical Inc
  • Vactech Oy
  • Wolwo Pharma
  • Wuhan Yicheng Biotechnology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll